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Abstract
Background: Patients, now generally well informed through dedicated websites and support organizations, are
beginning to look askance at clinical experimentation. We conducted a survey investigation to verify whether
women with endometriosis would still accept to participate in a randomized controlled trial (RCT) on treatment
for pelvic pain.
Methods: A total of 500 patients consecutively self-referring to an academic outpatient endometriosis clinic, were
asked to compile two questionnaires focused on hypothetical comparisons between a new drug and a standard
drug, and between medical and surgical treatment, for endometriosis-associated pelvic pain. The main outcome
measure was the percentage of patients willing to participate in a theoretical RCT.
Results: A total of 239 (48 %) women would decline participation in a comparative study on a new drug and a
standard drug, as 204 (41 %) would prefer the former medication, and 35 (7 %) the latter. Fifty women (10 %) would
participate in a RCT, but only 24 (5 %) would accept blinding. The most frequently chosen option was the patient
preference trial (211; 42 %). No significant differences were observed in demographic and clinical characteristics
between the 50 women who would accept and the 450 who would decline to be enrolled in a RCT. A total of 229
women (46 %) would decline participation in a comparative study on medical versus surgical treatment, as 186 (37 %)
would prefer pharmacological therapy and 43 (9 %) a surgical procedure. Only 11 (2 %) women would participate in
such a RCT. More than half of the women (260; 52 %) selected the patient preference trial. No significant variations in
distributions of answers were observed between women who did or did not undergo a previous surgical procedure.
Conclusion: Only a small minority of the women included in our study sample would accept randomization,
and even less so blinding. Patient preference appears to play a central role when planning interventional trials on
endometriosis-associated pelvic pain. Adequately designed observational analytic studies could be considered
when recruitment in a RCT appears cumbersome.
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Background
The randomized controlled trial (RCT) constitutes the
gold standard in the hierarchy of studies aimed at evalu-
ating the effect of treatments [1]. In a RCT, only the play
of chance and the effect of interventions may explain a
difference in outcome, and when chance is not a reason-
able explanation, then a variation in treatment effect
must be the source of that observed difference [2].
However, several obstacles are rendering gradually
more problematic the adoption of this study design
[3–8]. Strict regulatory requirements have greatly in-
creased the burden of administrative and bureaucratic
duties. Moreover, the costs for protocol approval, trial
monitoring, and insurance coverage are steadily rising.
In the endometriosis field, this is causing the progressive
fading of independent clinical investigation and prolifera-
tion of industry-sponsored trials, with potential conse-
quences on both, primary and secondary research [9–11].
In addition, ethical issues on randomization have been
described [12].
Also patients, now generally well informed through
dedicated websites and support organizations [13], are
beginning to look askance at clinical experimentation.
Kramer et al. [6] already pointed out the impediments to
clinical investigation deriving from reluctance of patients
to enroll in trials, and Braunstein et al. [14] reported that
a great proportion of interviewed trial participants felt
that they were likely to be “used” during clinical re-
search. The doubt here is whether, beyond ethical and
methodological considerations, women with endometri-
osis would still easily accept to participate in a RCT.
To answer this question, and to verify if a practical
problem of recruitment exists that would create an add-
itional major obstacle to the organization of high-quality
clinical research in endometriosis, we conducted a sur-
vey investigation on a series of consecutive women self-
referring to our outpatient endometriosis clinic.
Methods
This prospective, descriptive study was conducted in an
academic department specializing in the study and treat-
ment of endometriosis and was approved by the local ethics
committee (Comitato Etico della Fondazione IRCCS Ca’
Granda Ospedale Maggiore Policlinico, Milano, Italy, ap-
proval #247/2013). Italian women with a diagnosis of endo-
metriosis, consecutively self-referring for the first time to
our tertiary care outpatient clinic, were asked to participate
in a survey to investigate their opinion regarding a potential
participation in a hypothetical trial on treatment for pelvic
pain symptoms, and to assess their preferences for different
study designs. The objective of the survey was to define the
percentage of women who would be willing to participate
in a randomized, controlled trial.
Women were given written information on the research
activity of our center and the reasons for conducting clin-
ical studies. The various conditions amenable to drug
therapy and surgery were described. They were told that
the quality of study designs is important for the validity of
the results and, hence, for the consequent potential benefit
for all the patients with endometriosis. Explanations were
included on the types of trial that can be planned in order
to assess the efficacy of pharmacological therapy or to
compare medical with surgical treatment, and they were
informed that the most appropriate experimental design is
the double-blinded RCT, followed by the open RCT, and
finally by the observational analytic studies such as the
patient preference trial. Women were invited to ask ques-
tions in case of doubts, and the medical personnel of our
centre offered immediate clarifications. At the end of the
information phase, women who decided to participate in
the survey were requested to complete two simple
multiple-choice questionnaires on two hypothetical com-
parisons, one between two drugs and one between med-
ical therapy and surgical treatment, and to sign a written
informed consent in which it was stated that the compiled
questionnaires would be used for research purposes only.
The first questionnaire, focused on a hypothetical
comparison between a new drug and a standard drug for
pelvic pain associated with endometriosis (Fig. 1), and
included five different mutually exclusive preferences,
i.e., standard drug, new drug, RCT with allocation blind-
ing, RCT without blinding, and patient preference trial.
The second questionnaire focused on a hypothetical
comparison between a medical and surgical treatment
for endometriosis-associated pelvic pain (Fig. 2). Women
were invited to imagine that there was uncertainty on
which treatment was more effective, and that surgery
could be performed at laparoscopy with a risk of around
5 % of mostly minor complications. In addition, they
were informed that drugs generally control the disease
but do not cure it; on the other side, surgery must often
be combined with postoperative medical therapy in
order to limit the probability of symptoms and lesions
recurrence. In this case, only four mutually exclusive
choices were listed, i.e., medical treatment, surgical
treatment, RCT, and patient preference trial, as it was
deemed that a sham operation (RCT with allocation
blinding) would not be easily feasible in our hospital.
Before participants indicated their preferences by circ-
ling the chosen alternative on the two questionnaires,
they were informed that the study had only a descriptive
purpose and that their choices would not imply future
obligations or commitments. Collected demographic and
clinical information of participants included age, parity,
smoking, body mass index, education, previous medical
or surgical treatment, and types of medication used. Fre-
quency and severity of dysmenorrhea, deep dyspareunia
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and non-menstrual pelvic pain were measured according
to a 0–3 point multidimensional categorical rating scale
devised by Biberoglu and Behrman [15], and also using a 0
to 10 numerical rating scale, with 0 indicating the absence
of pain and 10 indicating the worst imaginable pain. Dis-
tribution of the above variables between participants who
accepted and those who declined the hypothesis of being
recruited in a RCT were compared using the Fisher's exact
test. To preserve a familywise type I error of 0.05, in
accordance with Bonferroni principle a difference was
regarded as statistically significant if P < 0.05/19 = 0.00263.
Results
During the first semester of 2014 a total of 500 women
were consecutively enrolled in the study. All the patients
were assisted by the National Health Service and no incen-
tives were offered to facilitate recruitment. No woman
refused to participate in the survey. The mean age of the
participants was 37 ± 8 years; 161 (32 %) were parous. A
total of 354 (71 %) patients were using or had used medical
treatments, whereas 301 (61 %) had undergone one or
more surgical procedures. The diagnosis in the 199 women
who did not undergo surgery was ovarian endometriomas
(n = 95), rectovaginal endometriosis (n = 75), bladder de-
trusor endometriosis (n = 15), deep lesions infiltrating the
pouch of Douglas and parametria (n = 10), and full-
thickness bowel lesions (n =4). Non-surgical diagnosis was
based on ultrasonographic criteria in patients with ovarian
endometriomas [16, 17]; on visual inspection of the poster-
ior fornix and biopsy of vaginal lesions in those with
rectovaginal endometriosis [18]; on ultrasonographic cri-
teria [19, 20], cystoscopic findings, and biopsy of vescical
lesions in those with bladder detrusor endometriosis; on
physical signs at recto-vaginal examination and ultrasono-
graphic criteria [21–23] in those with deep infiltrating
lesions; and on ultrasonographic criteria [24], and double
contrast barium enema and rectosigmoidoscopy/colonos-
copy findings in those with full-thickness bowel lesions.
Magnetic resonance imaging was performed in selected cir-
cumstances. All the women compiled both questionnaires.
Fig. 1 Questionnaire on willingness to participate in a study comparing a new and a standard drug
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A total of 239 (48 %) women would decline participa-
tion in a comparative study on a new drug and a stand-
ard drug for endometriosis-associated pelvic pain, as 204
(41 %) would prefer the former medication, and 35 (7 %)
the latter. Fifty women (10 %) would participate in a
RCT, but only 24 of them (5 %) would accept blinding.
The most frequently chosen option was the patient pref-
erence trial (211; 42 %; Table 1).
A total of 229 women (46 %) would decline participa-
tion in a comparative study on medical versus surgical
treatment for endometriosis-associated pelvic pain, as
186 (37 %) would prefer pharmacological therapy and 43
(9 %) a surgical procedure. Only 11 (2 %) women would
participate in a RCT. More than half of the women (260;
52 %) chose the patient preference trial as their favorite
option (Table 1).
Fig. 2 Questionnaire on willingness to participate in a study comparing medical and surgical treatment
Table 1 Summary of women’s responses to questionnaires on willingness to participate in comparative studies on treatments for
endometriosis
Women’s response Number %a
A. Willingness to participate in a study comparing a new and a standard drug
No, because of preference for the new drug 204 41
No, because of preference for the standard drug 35 7
Yes, and would accept both randomization and blinding 24 5
Yes, but would accept only randomization and not blinding 26 5
Yes, but would like to choose the drug after information 211 42
B. Willingness to participate in a study comparing medical and surgical treatment
No, because of preference for medical treatment 186 37
No, because of preference for surgical treatment 43 9
Yes, and would accept random allocation of treatments 11 2
Yes, but would like to choose treatment after information 260 52
aFigures are rounded to unity
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We also compared the 50 women who would accept to
be enrolled in a RCT on a new versus a standard drug,
with the 450 who would decline participation in such a
study (Table 2). The two subpopulations were substan-
tially similar, without significant differences. We did not
perform an analogous analysis for the questionnaire on
the study on medical versus surgical treatment, as the
group of accepters includes only 11 women, thus imped-
ing any meaningful conclusion.
In order to assess whether a previous surgical pro-
cedure could influence the women’s attitude toward
participation in a RCT, data were analyzed also ac-
cording to surgical or non-surgical diagnosis, but no
significant variations in distributions of answers were
observed (Table 2).
Discussion
The scenario emerging from this survey investigation
conducted on a study population of Italian women
with endometriosis, poses fundamental questions to
clinical investigators in this specific area of research.
In fact, only a small minority of patients would
accept enrollment in a RCT on the treatment of pel-
vic pain. If this situation is not limited to our referral
centre, generalizability of results of trials might be
prevented even when planning multicentre studies in
order to overcome difficulties in recruitment. In fact,
the external validity of trials conducted on extremely se-
lected study groups would be low, limiting the possibility
of extrapolating findings to a broader, heterogeneous
population.
Table 2 Characteristics of women accepting or declining to participate in a RCT comparing two different drugs
Characteristics Accepting RCT Declining RCT P
n = 50 n = 450
Age (years) 39.4 ± 7.3 37.3 ± 7.8 0.07
Previous deliveries 22 (44 %) 139 (31 %) 0.08
Smoking 3 (6 %) 93 (21 %) 0.013
BMI (Kg/m2) 22.6 ± 1.5 23.0 ± 2.5 0.31
Education 0.45
≤ 13 years 25 (50 %) 196 (44 %)
> 13 years 25 (50 %) 254 (56 %)
Previous surgery for endometriosis 0.59
None 19 (38 %) 180 (40 %)
One 24 (48 %) 186 (41 %)
≥ 2 7 (14 %) 84 (19 %)
Previous/current medical treatmentsa 35 (70 %) 319 (71 %) 0.87
Oral Contraceptives 21 (42 %) 193 (43 %) 1.00
Progestins 13 (26 %) 150 (33 %) 0.34
GnRH agonists 1 (2 %) 20 (4 %) 0.71
Non-conventional drugs 6 (12 %) 19 (4 %) 0.03
Dysmenorrhea
Biberoglu-Behrman grade 2-3 21 (42 %) 185 (41 %) 1.00
NRS≥ 8 14 (28 %) 149 (33 %) 0.53
Dyspareunia
Biberoglu-Behrman grade 2-3 9 (18 %) 91 (20 %) 0.85
NRS≥ 8 4 (8 %) 53 (12 %) 0.64
Chronic pelvic pain
Biberoglu-Behrman grade 2-3 7 (14 %) 77 (17 %) 0.69
NRS≥ 8 2 (4 %) 40 (9 %) 0.42
Use of analgesics 29 (58 %) 240 (53 %) 0.55
Number of days per monthb 3.9 ± 3.7 4.0 ± 3.3 0.93
aThe sum does not add up to the total because some women had used more than one medication
bRefers to those who use analgesics
Vercellini et al. BMC Women's Health  (2015) 15:89 Page 5 of 9
Moreover, a comparison between medical and surgical
therapy would be practically unfeasible, thus confirming
that patients are not prone to be casually allocated to
very different options [25–30]. This could potentially
further distort the evidence, as only selected RCTs could
be conducted (i.e., between two different medical treat-
ments, but not between a medical and a surgical treat-
ment), thus preventing complete assessment of all
available interventions, as previously suggested [31].
Women appear nowadays much better informed than in
the past, and wish to discuss treatment alternatives and to
choose the option that best fits with their personal needs
and expectations. In a sense, randomization impedes this
tailored choice. This is confirmed by the fact that the most
frequently selected option on both questionnaires was the
patient preference trial. In other words, only some pa-
tients seem to be still willing to participate in clinical
research and, in most cases, at their conditions, not at in-
vestigators’ conditions. In particular, 95 % of participants
in our survey would decline blinding.
A potential drawback of our study lies in the charac-
teristics of our participants, who are self-referred from
the entire country, and sometimes have already under-
gone unsuccessful medical treatments or surgical proce-
dures. Possibly, they might have a higher than usual
level of knowledge on their disease, and of information
on centers of expertise. It could be argued that this type
of survey should be conducted only on women who have
never been previously treated medically or surgically.
Yet, this collides with the possibility of obtaining a defin-
ite diagnosis in most patients. Moreover, a laparoscopy
performed with diagnostic purposes, eventually means
treating that patient surgically in case endometriosis is
found, as it would be unethical to visually confirm endo-
metriosis without excising the lesions. In addition, the
pattern of answers was not different in the 301 women
who had already undergone a surgical procedure and the
199 who were never operated, thus questioning the
impact of previous treatment on the study outcome. Fi-
nally, a misdiagnosis bias in the latter group appears
highly unlikely, as the diagnosis of endometriosis was
based on robust clinical, ultrasonographic, and histo-
logical evidence [32]. As study participants were all
assisted by the National Health Service, a potentially
spurious association between socioeconomic status and
propensity toward participation in clinical research can
be safely ruled out. More in general, clinical investiga-
tion is usually conducted in tertiary care centers thus
this appear to be the type of population that would be
considered for recruitment in a RCT anyway.
The groups of women that would accept or decline
randomization in a trial on medical treatment did not
differ significantly. However, our study was not originally
powered to investigate the distribution of baseline
characteristics between the two subgroups of women.
Indeed, the number of participants was large and women
were recruited consecutively, thus limiting the possibility
of selection bias. Patients were carefully instructed about
the different types of experimentation, on the objective
of the present survey, and on the hypothetical nature of
our inquiry, which would not have implied future obliga-
tions. They were allowed to ask questions and obtain clari-
fications by dedicated medical personnel. In addition, the
compilation of the two questionnaires was very simple
and could be performed rapidly. This helped avoiding
refusals to participate in the survey.
Women could not select more than one option. This
can be considered as another weakness of our survey
and may explain why the patient preference trial was the
most popular choice. Allowing women to choose more
than one study design option, and structuring questions
in a less “leading” format, would have probably helped
clarifying whether randomization was absolutely un-
acceptable or would be a possibility.
Several investigators recently focused on the growing
barriers to the conduct of RCTs, describing in details the
types of impediments and suggesting different modalities
to overcome unnecessary obstacles [5–8]. On the other
hand, estimates of effect size in large observational stud-
ies may be precise, but remain substantially weakened by
bias and confounding that only random allocation can
control [8]. Indeed, the problem here is different: in spite
of all shareable methodological considerations, RCTs in
the endometriosis area appear increasingly difficult to
conduct, at least in Italy, specifically because the vast
majority of patients would decline random allocation.
The adoption of the partially randomized patient pref-
erence trial design, in which participants who do not
accept randomization are allowed to chose their pre-
ferred intervention [33, 34] or of the response-adaptive
randomization trial design, in which the ratio of partici-
pants assigned to each arm are actively adjusted in favor
of the better performing intervention based on already
available data of patients previously recruited [35], does
not seem to overcome the basic issue of unwillingness to
accept randomization. In any case, the resulting group
of women allocated by chance would be too small to be
representative of the population of women with endo-
metriosis. Moreover, the administrative burden and the
costs would be substantially the same as for the standard
two-arm clinical trial design.
To complete their studies, several investigators con-
ducted part of the trial based on random allocation of
treatments, and part based on patient preference [25, 26,
29, 36]. Interestingly, more patients generally chose the
patient preference option than the random allocation
one. Moreover, both the estimates of effect size and its
precision were substantially similar in the two study
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populations [25, 26, 29, 36]. Additionally, it has been re-
ported that the results of well-designed observational
studies are generally similar to those of formal RCTs [37,
38]. Therefore, when preferences based on informed ex-
pectations exist, observational methods may be an alter-
native to RCTs [39, 40].
When the objective is the comparison of already ap-
proved treatments for endometriosis (i.e., phase IV studies,
thus excluding truly novel, experimental interventions),
observational studies are easier and less costly to conduct
than RCTs, can be carried out in “real world” patient pop-
ulations, and can be prolonged for longer periods on a
large number of participants, thus providing robust evi-
dence on safety of interventions [2]. As treatments are not
allocated randomly, multivariable statistical models must
be adopted to control for potential bias and confounding
factors. The physician’s selection of patients who should
receive the treatment constitutes one of the main con-
founders in observational studies. Therefore, it is important
to try to limit this bias. Considering the two hypothetical
comparisons of our survey, two different study designs
could be adopted when RCTs appear unfeasible.
When large differences exist in the type of treatments
to be compared and in associated morbidity (in our sur-
vey, medical versus surgical treatment), the patient pref-
erence trial might constitute a practical alternative.
Differently from an observational study comparing two
case series, where clinicians allocate treatments, in the
patient preference, parallel cohort trial, treatment alloca-
tion is by patient choice. Whereas clinicians may be
prone to recruit different types of women to the two
study arms, allocation by the patients themselves should
improve external validity. It has been suggested that
preference-based treatment allocation may optimize
cost-effectiveness of intervention [41], also because this
research environment may be more similar to practical
life conditions [33]. In case of functional outcomes, a
comparison between two groups of participants who
have chosen their treatment emphasizes patient satisfac-
tion, thus representing the maximum possible effect size
of the intervention [42]. However, a major selection bias is
introduced in a study based completely on patient prefer-
ence, thus limiting the interpretation of the findings.
Moreover, the effect observed under these conditions can
be referred exclusively to patients who specifically choose
that treatment [43].
When two similar treatments are being compared
(e.g., a new versus an old progestin, or a progestin versus
a combined oral contraceptive), the patient-preference
trial design does not seem suitable, as women may not
be able to clearly express a definite preference. In these
cases, the before and after study (or pre-post study), a
quasi-experimental design, may be an option [44]. The
before and after study is usually adopted at a system
level (clinics, hospitals) to compare outcomes before and
after an intervention is implemented [45]. A before and
after study design could be used also to evaluate treat-
ments, provided some conditions are satisfied. In this case
all new cases of patients with symptomatic endometriosis
would receive the same, standard medical therapy for a
pre-planned period of time, at the end of which all new
cases with the same clinical characteristics would receive
the new medical treatment for the same period of time.
The study gauges the difference in the effect of the new
drug compared with that of the standard one.
In order to infer that a variation in outcomes is the
consequence of the implementation of the new treat-
ment, the characteristics of the participants in the “be-
fore group” must be similar to those in the “after group”,
otherwise such inference would be seriously flawed. In
order to avoid a selection bias, all eligible patients ob-
served before the introduction of the new intervention
must be included in the “before group”, the new treat-
ment must be implemented at a precise time point, and
all eligible patients observed after that cut-off time must
use only the new treatment and be included in the “after
group”. Any admixture of different treatments during
the study period would invalidate the findings. There
should also be no evidence of a prevailing temporal
trend. Still, without a control group of patients in whom
no variation in the intervention has been implemented,
it may reveal difficult to ascribe differences in outcomes
to the change of medical treatment. Moreover, only ran-
dom allocation of treatments allows genuine comparabil-
ity of the study groups. In a before and after study, even
a modification in referral pattern during the study period
may result in the creation of populations that may differ
for several characteristics, such as severity of symptoms
or type of lesions. Since it is unlikely to be able tocontrol
for all known and unknown characteristics that may in-
fluence the outcome, it may not be possible to exclude
that any observed between-group difference in a before
and after study is due to confounding [45].
Conclusion
The surprising findings of this survey should be considered
as an impediment that our community must try to over-
come. Indeed, the quality of the evidence derived from ob-
servational studies remains suboptimal even under the best
research conditions. In particular, generalizability of results
of patient preference trials is limited, and inferences from
pre–post studies should be regarded as being based on
circumstantial evidence. More in general, observational
studies may be viewed as a mean to investigate whether in-
terventions that have already been proven to work under
ideal circumstances (that is, in RCTs), work also in non-
selected populations, and which treatment alternative
works best in real life. In other words, observational studies
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can be used to evaluate efficiency, although they are not
suited to assess efficacy, that is whether a new, experimental
treatment can work. Therefore, observational studies may
be useful for defining the role of the available therapeutic
armamentarium in different everyday clinical conditions.
However, experimental treatments that could interfere with
the pathogenic mechanism(s) of endometriosis are indeed
needed. Thus, the conduction of RCTs remains a priority.
Different strategies could be adopted to make patients
understand that participating in RCTs is in the best inter-
est of all women with the disease. The engagement of
patients could be increased by including them in the selec-
tion of therapies, design of protocol, recruitment, and
writing of lay summaries and scientific articles [46–50].
According to some authors [51], patients have a greater
ability, compared with clinicians, to prioritize the out-
comes they truly value, identify obstacles to trial enrol-
ment, and help discover what works in the real world, not
just in research settings. Moreover, health authorities and
scientific societies should increase their educational initia-
tives toward citizens, clarifying the advantages of well-
conducted clinical investigation and explaining the benefit
for the entire population that derives from it. In this
regard, patients associations could play a crucial role,
disseminating factual information and encouraging par-
ticipation in trials. In the end, accepting enrolment in a
RCT is an act of generosity that entails a high sense of
social responsibility.
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